Hepatic Disease in Patients With HIV
Summary
- Highly active DAA regimens are now recommended as part of preferred or alternative regimens for persons with HIV and HCV coinfection by the AASLD/IDSA (Management Guidelines)[AASLD-IDSA HCV] and EASL (Management Guidelines)[EASL HCV] guidance panels Treatment of Persons Coinfected With HIV and Genotype 1 HCV
- AASLD/IDSA and EASL guidance panels recommend highly active DAA regimens for genotype 1 HCV/HIV–coinfected patients (Management Guidelines)[AASLD-IDSA HCV] (Management Guidelines)[EASL HCV]
- AASLD/IDSA guidance panel recommends highly active DAA regimens as preferred therapy for HCV treatment of persons with HIV and genotype 2-6 HCV coinfection (Table 10) (Management Guidelines)[AASLD-IDSA HCV]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content